EyePoint is currently undervalued, with a market capitalization of $151.02 million.
Bears say
EyePoint is facing several major risks, including the potential for regulatory delays or failure to gain approval for their EYP-1901 product, competition from larger companies in the wet AMD space, and the need for additional capital before becoming profitable. While early data for their DURAVYU and EYP-2301 products appear promising, there are concerns about the long-term efficacy of these treatments and their potential side effects. Overall, the negative outlook on EyePoint's stock is driven by these various risks and uncertainties related to the success and commercial viability of their products.
EyePoint Pharmaceuticals (EYPT) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.
This aggregate rating is based on analysts' research of EyePoint Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Get the latest EyePoint Pharmaceuticals (EYPT) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis
FAQs About EyePoint Pharmaceuticals (EYPT) Forecast
Analysts have given EyePoint Pharmaceuticals (EYPT) a Strong Buy based on their latest research and market trends.
According to 7 analysts, EyePoint Pharmaceuticals (EYPT) has a Strong Buy consensus rating as of Jul 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.
Wall Street analysts have set a price target of $46, reflecting a 0.00% increase from the current stock price.
Financial analysts have set a price target of $46, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.
Get the latest EyePoint Pharmaceuticals (EYPT) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.